BioCentury | Nov 14, 2020
Politics, Policy & Law

U.K.’s opportunity as changes come to MHRA, NICE

On the cusp of a new era outside of Europe, the U.K. has an opportunity to create an innovative and interconnected regulatory and reimbursement system that can attract biopharma by accelerating patient...
BioCentury | Oct 30, 2020
Product Development

TransCelerate looks to sustain momentum of data sharing post-pandemic

TransCelerate hopes to continue broadening access to shared clinical trial data in the post-pandemic era, but whether it can do so depends on the willingness of its member companies to embed the COVID-driven...
BioCentury | Oct 1, 2020
Product Development

‘Flipting’ the switch: a technological prescription for lower drug costs

It is time to do away with the middlemen that drive up drug costs for patients through their complex system of kickbacks. This week’s House committee hearings on drug pricing are a sign the...
BioCentury | Sep 11, 2020
Deals

Data Bytes: upfront tally shows 2020’s dealmakers playing catch-up

Biopharmas need to plunk down at least $8.5 billion by year-end if the sector’s dealmakers hope to match last year’s disclosed upfront payments of $17.9 billion. BioCentury has tracked $9.4 billion raised from January through...
BioCentury | Sep 11, 2020
Product Development

Governments must work alongside industry to fill the cracks exposed by COVID-19 before the next, inevitable, pandemic

This is the fifth and final article in BioCentury’s 28th Annual Back to School package. In the opening piece, BioCentury called on biopharma to convert its COVID response to a new era of efficient...
BioCentury | Sep 10, 2020
Product Development

Master protocols should not be a one-off phenomenon confined to COVID-19

This is the fourth article in BioCentury’s 28th Annual Back to School package. In the opening piece, BioCentury called on biopharma to convert its COVID response to a new era of efficient drug development. ...
BioCentury | Sep 10, 2020
Product Development

Medicxi’s de Rubertis hopes for positive future for infectious disease after COVID-19: a BioCentury audio interview

Francesco de Rubertis, co-founder and partner of Medicxi, is optimistic that the COVID-19 pandemic might lead to an increased interest in infectious disease investment, but it will take government action to create the incentives. de...
BioCentury | Sep 10, 2020
Product Development

Having touched the third rail of data sharing in the pandemic, drug developers should hold on tight

This is the third article in BioCentury’s 28th Annual Back to School package. In the opening piece, BioCentury called on biopharma to convert its COVID response to a new era of efficient drug development. ...
BioCentury | Sep 9, 2020
Product Development

Networking that fueled COVID-19 response should spill into digital sciences and more, says Genmab’s van de Winkel: a BioCentury audio interview

Jan van de Winkel sees a strong future for data sharing and more master protocol trials, fueled by increasing adoption of digital sciences, as companies turn the collaboration they’ve shown in COVID-19 into longer-term productive...
BioCentury | Sep 8, 2020
Product Development

Biopharmas must address the reality of racial disparities in health outcomes exposed by COVID-19

This is the second article in BioCentury’s 28th Annual Back to School package. In the opening piece, BioCentury called on biopharma to convert its COVID response to a new era of efficient drug development...
Items per page:
1 - 10 of 228